Safety and allele-specific immunogenicity of a malaria vaccine in Malian adults: results of a phase I randomized trial.

ABSTRACT:

Objectives

The objectives were to evaluate the safety, reactogenicity, and allele-specific immunogenicity of the blood-stage malaria vaccine FMP1/AS02A in adults exposed to seasonal malaria and the impact of natural infection on vaccine-induced antibody levels.

Design

We conducted a randomized, double-blind, controlled phase I clinical trial.

Setting

Bandiagara, Mali, West Africa, is a rural town with intense seasonal transmission of Plasmodium falciparum malaria.

Participants

Forty healthy, malaria-experienced Malian adults aged 18-55 y were enrolled.

Interventions

The FMP1/AS02A malaria vaccine is a 42-kDa recombinant protein based on the carboxy-terminal end of merozoite surface protein-1 (MSP-1(42)) from the 3D7 clone of P. falciparum, adjuvanted wit

SUBMITTER: Thera MA 

PROVIDER: S-EPMC1851722 | biostudies-literature | 2006 Nov

REPOSITORIES: biostudies-literature